2-thiomorpholinobenzaldehyde | 736990-84-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻嗪类
• 英文名称: 2-thiomorpholinobenzaldehyde
• 英文别名: 2-thiomorpholin-4-ylbenzaldehyde
• CAS: 736990-84-4
• 化学式: C₁₁H₁₃NOS
• 分子量: 207.296
• InChiKey: KBXXPBRWDYNWBB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  45.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-thiomorpholinobenzaldehyde 在 potassium fluoride 、 盐酸二甲胺 、 gadolinium(III) trifluoromethanesulfonate 作用下， 以 甲苯 为溶剂， 反应 186.0h， 生成
  参考文献：
  名称：

  研究[1,5]-氢化物的转变作为硝基-曼尼希环化的途径

  摘要：

  发现了[1,5]-氢化物转移硝基-曼尼希反应的条件，该条件导致了2,3-二取代的四氢喹啉的合成。通过在HFIP中回流，两种简单的环状胺底物可分别以65％和90％的收率得到非对映体纯的重排产物。一种更通用的方法是使用Gd（OTf）3作为催化剂，并以42：84％的产率成功重排其他环状和无环胺，非对映体比例为75:25至> 95：5，有利于抗非对映异构体（9个实例） 。含硫杂环的两个实例给出的产率较低，分别为9％和25％。吸电子取代基显示出对反应成功具有有害作用。结果表明，[1,5]-氢化物转移硝基-曼尼希反应相对于中间体亚胺离子的稳定性有局限性。

  DOI：

  10.1016/j.tet.2019.130663
• 作为产物：
  描述：

  硫代吗啉 、 邻溴苯甲醛 在 palladium diacetate 、 caesium carbonate 、 R-(+)-1,1'-联萘-2,2'-双二苯膦 作用下， 以 甲苯 为溶剂， 反应 18.08h， 生成 2-thiomorpholinobenzaldehyde
  参考文献：
  名称：

  研究[1,5]-氢化物的转变作为硝基-曼尼希环化的途径

  摘要：

  发现了[1,5]-氢化物转移硝基-曼尼希反应的条件，该条件导致了2,3-二取代的四氢喹啉的合成。通过在HFIP中回流，两种简单的环状胺底物可分别以65％和90％的收率得到非对映体纯的重排产物。一种更通用的方法是使用Gd（OTf）3作为催化剂，并以42：84％的产率成功重排其他环状和无环胺，非对映体比例为75:25至> 95：5，有利于抗非对映异构体（9个实例） 。含硫杂环的两个实例给出的产率较低，分别为9％和25％。吸电子取代基显示出对反应成功具有有害作用。结果表明，[1,5]-氢化物转移硝基-曼尼希反应相对于中间体亚胺离子的稳定性有局限性。

  DOI：

  10.1016/j.tet.2019.130663

文献信息

• Hydride Transfer Initiated Redox-Neutral Cascade Cyclizations of Aurones: Facile Access to [6,5] Spirocycles
  作者：Kang Duan、Xiao-De An、Long-Fei Li、Lian-Lian Sun、Bin Qiu、Xian-Jiang Li、Jian Xiao

  DOI：10.1021/acs.orglett.0c00309

  日期：2020.4.3

  Reported herein is the hydride transfer initiated redox-neutral cascade cyclizations of aurones, providing a variety of [6,5] spiro-heterocycles in satisfactory yields and good diastereoselectivities.

  本文报道的是氢化物转移引发的氧化还原中性级联环氧化，可提供令人满意的收率和良好的非对映选择性的各种[6,5]螺杂环。
• [EN] MITOGEN ACTIVATED PROTEIN KINASE-ACTIVATED PROTEIN KINASE-2 INHIBITING COMPOUNDS<br/>[FR] COMPOSES INHIBANT LA PROTEINE KINASE-2 ACTIVEE PAR LA PROTEINE KINASE ACTIVEE PAR DES AGENTS MITOGENES
  申请人：PHARMACIA CORP

  公开号：WO2004058762A1

  公开（公告）日：2004-07-15

  Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of using such compounds for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNFα, are described, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Therapeutic compositions, pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.

  本文描述了抑制有丝分裂原活化蛋白激酶激活蛋白激酶2（MK-2）的化合物。描述了使用这些化合物来抑制MK-2，以及预防或治疗由TNFα介导的疾病或障碍的方法，其中该方法涉及向受试者施用本发明的MK-2抑制剂化合物。还描述了包含本MK-2抑制剂化合物的治疗组合物、药物组合物和试剂盒。
• Mitogen activated protein kinase-activated protein kinase-2 inhibiting compounds
  申请人：Pharmacia Corporation

  公开号：US20040209897A1

  公开（公告）日：2004-10-21

  Compounds are described which inhibit mitogen activated protein kinase-activated protein kinase-2 (MK-2). Methods of using such compounds for the inhibition of MK-2, and for the prevention or treatment of a disease or disorder that is mediated by TNF&agr;, are described, where the method involves administering to the subject an MK-2 inhibiting compound of the present invention. Therapeutic compositions, pharmaceutical compositions and kits which contain the present MK-2 inhibiting compounds are also described.

  本文描述了抑制有丝分裂原活化蛋白激酶激活蛋白激酶-2（MK-2）的化合物。本文还描述了使用这些化合物来抑制MK-2并预防或治疗由TNFα介导的疾病或障碍的方法，其中该方法涉及向受试者施用本发明的MK-2抑制化合物。本文还描述了包含本MK-2抑制化合物的治疗组合物、制药组合物和试剂盒。
• CAMPTOTHECIN DERIVATIVE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
  申请人：Marine Biomedical Research Institute Of Qingdao Co., Ltd.

  公开号：EP3808751A1

  公开（公告）日：2021-04-21

  The present invention is directed to compounds according to Formula I as well as to stereisomer, tautomer or pharmaceutically acceptable salts of such compounds. The invention also is directed to pharmaceutically acceptable compositions containing such compounds and associated methods for preparing and effect dose in treatment as well as the application in preparing medicine for preventing and/or treating cancers. The invention provides the novel derivatives which introduce methylenedioxy in the position of 10,11 and different groups in the position of 7. The derivatives of novel structure, and the raw materials are easily to obtain. In addition, the compounds in this invention have good cytotoxic activity in vitro and anti-tumor activity in vivo. Therefore, this kind of compounds have broad application foreground. The structure of derivatives are as follows:

  本发明涉及根据式 I 的化合物以及此类化合物的立体异构体、同系物或药学上可接受的盐。本发明还涉及含有此类化合物的药学上可接受的组合物、相关的制备方法和治疗效果剂量，以及在制备预防和/或治疗癌症的药物中的应用。本发明提供了在 10、11 位置引入亚甲基二氧和在 7 位置引入不同基团的新型衍生物，该衍生物结构新颖，原料易得。此外，本发明中的化合物具有良好的体外细胞毒性活性和体内抗肿瘤活性。因此，此类化合物具有广阔的应用前景。衍生物的结构如下
• Design, synthesis and anticancer activity of functionalized spiro-quinolines with barbituric and thiobarbituric acids
  作者：Ravi Kiran Bhaskarachar、Vijayakumar G. Revanasiddappa、Subramanya Hegde、Janardhana P. Balakrishna、Suman Y. Reddy

  DOI：10.1007/s00044-015-1408-7

  日期：2015.9

  A new series of spiro-quinoline compounds have been accomplished by the reaction of barbituric acid or thiobarbituric acid with derivatives of benzisoxazole-5-carbaldehyde or 2-substituted benzaldehyde. These compounds were evaluated for their in vitro cytotoxicity on two mammalian cancer cell lines MCF-7 and KB. The compounds exhibit cytotoxicity against these cell lines in micromolar range. Among the series of compounds, 11(a-j) particularly 11b and 11e showed relatively good activity against both the tested cell lines. Compound 11b was found to exhibit the highest cytotoxic activity with IC50 value 90.2 mu M for MCF-7 and 49.8 mu M for KB cell line. Flow cytometric analysis study confirmed that these molecules induced cytotoxicity via apoptosis.